<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246155</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52120-103</org_study_id>
    <nct_id>NCT00246155</nct_id>
  </id_info>
  <brief_title>Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain</brief_title>
  <official_title>A Prospective Study to Evaluate the Potential Effects on Function and Size in Back Muscle After Injection of Botulinum Toxin Type A (Dysport®) in the Treatment of Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse the changes in back muscle size and strength
      following use of Dysport®, and to establish whether there is any association between pain
      reduction and change in strength, in patients suffering from chronic low back pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction as assessed by the mean Visual Analogue Scale (VAS) during last 2 weeks. Assessments will be made at the initial time before injection and 1, 2, 3 months after injection.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in daily life activities and quality of life using the Oswestry Low Back Pain Questionnaire (OLBPQ), and Short Form-36 (SF-36). Assessments will be made at the initial time before injection and 1, 2, 3 months after injection.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the total isometric lumbar extensor strength and separated angle using lumbar MedX machine.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between pain reduction and strength. Measurements will be performed at baseline, and 1, 2, 3 months after injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the lumbar extensor muscular size in CT Measurement will be performed at baseline and 3 months after injection.</measure>
  </secondary_outcome>
  <enrollment>35</enrollment>
  <condition>Low Back Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A (Dysport)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffering from muscular low back pain (between L-1 and S-1 level).

          -  Symptoms of more than six months duration.

          -  No benefit from previous treatments.

          -  Patient must present with bilaterally more than 2 active trigger points (TrPs) in the
             region of the low back musculature.

          -  CT scan or MRI examination of the lumbar spine was performed within the past year.

          -  Absence of significant pathology, such as bone fracture, nerve damage or severe
             psychiatric condition.

        Exclusion Criteria:

          -  Constant or persistent severe pain due to nerve root compression or fibromyalgia.

          -  The patient has received surgery on the spine.

          -  Other musculoskeletal disabilities e.g. myasthenia gravis, or disorders of the
             neuromuscular junction.

          -  Any serious pathology, such as cancer, systemic inflammatory disease, vertebral
             fractures, neurological signs, spinal infection.

          -  Epidural injection of local anaesthetics and steroids within 12 weeks proceeding
             inclusion.

          -  Trigger point injection of local anaesthetics and steroid within 8 weeks proceeding
             inclusion.

          -  Pain associated with urinary tract infections, or gynaecological disorders.

          -  Bleeding disturbances or currently using coumarin derivatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lempereur, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wooridul Spine Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-100</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2005</study_first_submitted>
  <study_first_submitted_qc>October 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <last_update_submitted>October 10, 2006</last_update_submitted>
  <last_update_submitted_qc>October 10, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2006</last_update_posted>
  <keyword>chronic</keyword>
  <keyword>muscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

